[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN106265736A - 一种复方黄芪多糖注射液制备方法及应用 - Google Patents

一种复方黄芪多糖注射液制备方法及应用 Download PDF

Info

Publication number
CN106265736A
CN106265736A CN201610657699.8A CN201610657699A CN106265736A CN 106265736 A CN106265736 A CN 106265736A CN 201610657699 A CN201610657699 A CN 201610657699A CN 106265736 A CN106265736 A CN 106265736A
Authority
CN
China
Prior art keywords
radix astragali
application
water
compound radix
injection preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610657699.8A
Other languages
English (en)
Inventor
成青兰
胡春灿
成劲
彭静波
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhuzhou Shennong Animal Pharmaceutical Co Ltd
Original Assignee
Zhuzhou Shennong Animal Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhuzhou Shennong Animal Pharmaceutical Co Ltd filed Critical Zhuzhou Shennong Animal Pharmaceutical Co Ltd
Priority to CN201610657699.8A priority Critical patent/CN106265736A/zh
Publication of CN106265736A publication Critical patent/CN106265736A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明公开了一种复方黄芪多糖注射液制备方法及应用，其特征在于，包括以下成分：黄芪多糖1kg‑2kg、双链聚肌胞30g‑100g、安乃近10kg‑30kg、地塞米松磷酸钠50g‑100g、肌苷1kg‑2kg、乙醇10000ml—20000ml、乙二胺四乙酸二钠7g‑10g、无水亚硫酸钠70g‑100g、活性炭300g‑500g、其余为水。该复方黄芪多糖注射液制备方法及应用，提高免疫活性，增加免疫器官的重量，能使环磷酰胺造成的免疫抑制转至正常水平，还可以刺激机体产生非特异性抗体，使皮肤血管扩张，血流加速，散热加速而降低体温，抗过敏、降温、快速恢复病畜禽食欲等功效，以上几种药物合理制备，针对病毒性感染同时进行对因和对症治疗，抑制病毒复制，提高机体免疫力，提高疫苗应答水平，缓解临床症状，促进病畜禽快速恢复。

Description

一种复方黄芪多糖注射液制备方法及应用
技术领域
本发明涉及生物医药制制造技术领域，尤其涉及一种复方黄芪多糖注射液制备方法及应用。
背景技术
近年来，为了保证人类健康，兽医上大部分常用抗病毒药物如吗啉双胍、利巴韦林、金刚烷胺已在禁止之列，广谱抗病毒已到了无药可用的地步。同时，我国由南到北的许多猪场和散养户爆发一种以高热、传染快、食欲不振甚至废绝、死亡率高的怪病，有些猪场甚至因此“全军覆没”，经农业部组织有关专家现场诊断和分析，诊断为多种病毒和细菌、支原体属(包括肺炎支原体、附红细胞体)弓形体的混合感染引起的猪无名高热病。其中高致病性蓝耳病毒为主要病原，抑制机体免疫系统，引起免疫失败。许多专家开始把这种病当弓形体病，附红细胞体病来防治，后又单纯地当蓝耳病、流感、猪瘟来防治，结果均以失败而告终，养殖户盲目用药，而单方药物防治效果极差，导致死亡率极高，一度引起广大养殖户恐慌，因此研发一种复方制剂能抑制多种病毒复制，激活机体免疫系统，提高机体免疫应答水平的药物，不仅是畜牧业发展的需要，也势在必行。
发明内容
基于背景技术存在的技术问题，本发明提出了一种复方黄芪多糖注射液制备方法及应用，抑制病毒复制，提高机体免疫力，提高疫苗应答水平，缓解临床症状，促进病畜禽快速恢复。
本发明提供如下技术方案：一种复方黄芪多糖注射液制备方法及应用，其特征在于，包括以下成分：
黄芪多糖1kg-2kg、双链聚肌胞30g-100g、安乃近10kg-30kg、地塞米松磷酸钠50g-100g、肌苷1kg-2kg、乙醇10000ml—20000ml、乙二胺四乙酸二 钠7g-10g、无水亚硫酸钠70g-100g、活性炭300g-500g、其余为水。
优选的，所述黄芪多糖由己糖醛酸、葡萄糖、果糖、鼠李糖、阿拉伯糖、半乳糖醛酸和葡萄糖醛酸组成。
优选的，包括以下成分：
黄芪多糖1.5kg、双链聚肌胞70g、安乃近20kg、地塞米松磷酸钠75g、肌苷1.5kg、乙醇15000ml、乙二胺四乙酸二钠8.5g、无水亚硫酸钠85g、活性炭400g、其余为水。
优选的，步骤如下：
复方黄芪多糖注射液的制备：首先称取黄芪多糖1kg-2kg加入搅拌装置中并进行溶解，过夜后再对其进行过滤，接着称取双链聚肌胞30g-100g加入到搅拌装置中进行溶解，取注射用的少量水，再称取地塞米松磷酸钠50g-100g加入搅拌搅装置中进行搅拌溶解，然后再取少量注射用水，称取安乃近10kg-30kg和肌苷1kg-2kg加入刀搅拌装置中进行搅拌溶解，继续取少量注射用水，加入无水亚硫酸氢钠70g-100g、乙二胺四乙酸二钠7g-10g加入到搅拌搅拌罐中进行溶解混合，同时加入乙醇10000ml-20000ml和活性炭300g-500g并进行均匀搅拌，静置脱色后再进行过滤，然后加水至全量，调节PH值6.1-6.4并进行灌封灭菌后从而获得成品。
优选的，应用范围为：
兽药方面：预防和治疗家禽、家畜、水产类病毒性疾病，主要用于激活免疫细胞淋巴细胞，不仅可以刺激机体产生白介素和干扰素，还可以刺激机体产生非特异性抗体。
本发明提供了一种复方黄芪多糖注射液制备方法及应用，采用黄芪多糖，其具有免疫刺激作用，促进机体免疫器官的发育，提高免疫活性，增加免疫器官的重量，能使环磷酰胺造成的免疫抑制转至正常水平，采用双链聚肌胞，不仅可以刺激机体产生白介素和干扰素，还可以刺激机体产生非特异性抗体， 采用安乃近，使皮肤血管扩张，血流加速，出汗增加，散热加速而降低体温，并通过地塞米松磷酸钠和安乃近有抗炎、抗过敏、降温、快速恢复病畜禽食欲等功效，肌苷可以及时补充能量，以上几种药物合理制备，针对病毒性感染同时进行对因和对症治疗，抑制病毒复制，提高机体免疫力，提高疫苗应答水平，缓解临床症状，促进病畜禽快速恢复。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
下面结合一些实施例对本发明作进一步解释，应该理解以下实施例旨在说明，不应被视为对本发明的限制。
实施例一
一种复方黄芪多糖注射液制备方法及应用，步骤如下：
首先称取黄芪多糖1kg加入搅拌装置中并进行溶解，过夜后再对其进行过滤，接着称取双链聚肌胞30g加入到搅拌装置中进行溶解，取注射用的少量水，再称取地塞米松磷酸钠50g加入搅拌搅装置中进行搅拌溶解，然后再取少量注射用水，称取安乃近10kg和肌苷1kg加入刀搅拌装置中进行搅拌溶解，继续取少量注射用水，加入无水亚硫酸氢钠70g、乙二胺四乙酸二钠7g加入到搅拌搅拌罐中进行溶解混合，同时加入乙醇10000ml和活性炭300g并进行均匀搅拌，静置脱色后再进行过滤，然后加水至全量，调节PH值6.1。
实施例二
一种复方黄芪多糖注射液制备方法及应用，步骤如下：
首先称取黄芪多糖1.5kg加入搅拌装置中并进行溶解，过夜后再对其进行过滤，接着称取双链聚肌胞70g加入到搅拌装置中进行溶解，取注射用的 少量水，再称取地塞米松磷酸钠75g加入搅拌搅装置中进行搅拌溶解，然后再取少量注射用水，称取安乃近20kg和肌苷1.5kg加入刀搅拌装置中进行搅拌溶解，继续取少量注射用水，加入无水亚硫酸氢钠85g、乙二胺四乙酸二钠8.5g加入到搅拌搅拌罐中进行溶解混合，同时加入乙醇15000ml和活性炭400g并进行均匀搅拌，静置脱色后再进行过滤，然后加水至全量，调节PH值6.25并进行灌封灭菌后从而获得成品。
实施例三
一种复方黄芪多糖注射液制备方法及应用，步骤如下：
首先称取黄芪多糖2kg加入搅拌装置中并进行溶解，过夜后再对其进行过滤，接着称取双链聚肌胞100g加入到搅拌装置中进行溶解，取注射用的少量水，再称取地塞米松磷酸钠100g加入搅拌搅装置中进行搅拌溶解，然后再取少量注射用水，称取安乃近30kg和肌苷2kg加入刀搅拌装置中进行搅拌溶解，继续取少量注射用水，加入无水亚硫酸氢钠100g、乙二胺四乙酸二钠10g加入到搅拌搅拌罐中进行溶解混合，同时加入乙醇20000ml和活性炭500g并进行均匀搅拌，静置脱色后再进行过滤，然后加水至全量，调节PH值6.4并进行灌封灭菌后从而获得成品。
以上所述，仅为本发明较佳的具体实施方式，但本发明的保护范围并不局限于此，任何熟悉本技术领域的技术人员在本发明揭露的技术范围内，根据本发明的技术方案及其发明构思加以等同替换或改变，都应涵盖在本发明的保护范围之内。

Claims (5)

1.一种复方黄芪多糖注射液制备方法及应用，其特征在于，包括以下成分；
黄芪多糖1kg-2kg、双链聚肌胞30g-100g、安乃近10kg-30kg、地塞米松磷酸钠50g-100g、肌苷1kg-2kg、乙醇10000ml-20000ml、乙二胺四乙酸二钠7g-10g、无水亚硫酸钠70g-100g、活性炭300g-500g、其余为水。
2.根据权利要求1所述的一种复方黄芪多糖注射液制备方法及应用，其特征在于：所述黄芪多糖由己糖醛酸、葡萄糖、果糖、鼠李糖、阿拉伯糖、半乳糖醛酸和葡萄糖醛酸组成。
3.根据权利要求1所述的一种复方黄芪多糖注射液制备方法及应用，其特征在于：包括以下成分：
黄芪多糖1.5kg、双链聚肌胞70g、安乃近20kg、地塞米松磷酸钠75g、肌苷1.5kg、乙醇15000ml、乙二胺四乙酸二钠8.5g、无水亚硫酸钠85g、活性炭400g、其余为水。
4.根据权利要求1、2或3所述的一种复方黄芪多糖注射液制备方法及应用，其特征在于，步骤如下：
复方黄芪多糖注射液的制备：首先称取黄芪多糖1kg-2kg加入搅拌装置中并进行溶解，过夜后再对其进行过滤，接着称取双链聚肌胞30g-100g加入到搅拌装置中进行溶解，取注射用的少量水，再称取地塞米松磷酸钠50g-100g加入搅拌搅装置中进行搅拌溶解，然后再取少量注射用水，称取安乃近10kg-30kg和肌苷1kg-2kg加入刀搅拌装置中进行搅拌溶解，继续取少量注射用水，加入无水亚硫酸氢钠70g-100g、乙二胺四乙酸二钠7g-10g加入到搅拌搅拌罐中进行溶解混合，同时加入乙醇10000ml-20000ml和活性炭300g-500g并进行均匀搅拌，静置脱色后再进行过滤，然后加水至全量，调节PH值6.1-6.4并进行灌封灭菌后从而获得成品。
5.根据权利要求1所述的一种复方黄芪多糖注射液制备方法及应用，其特征在于，应用范围为：
兽药方面：预防和治疗家禽、家畜、水产类病毒性疾病，主要用于激活免疫细胞淋巴细胞，不仅可以刺激机体产生白介素和干扰素，还可以刺激机体产生非特异性抗体。
CN201610657699.8A 2016-08-12 2016-08-12 一种复方黄芪多糖注射液制备方法及应用 Pending CN106265736A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610657699.8A CN106265736A (zh) 2016-08-12 2016-08-12 一种复方黄芪多糖注射液制备方法及应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610657699.8A CN106265736A (zh) 2016-08-12 2016-08-12 一种复方黄芪多糖注射液制备方法及应用

Publications (1)

Publication Number Publication Date
CN106265736A true CN106265736A (zh) 2017-01-04

Family

ID=57669285

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610657699.8A Pending CN106265736A (zh) 2016-08-12 2016-08-12 一种复方黄芪多糖注射液制备方法及应用

Country Status (1)

Country Link
CN (1) CN106265736A (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107385085A (zh) * 2017-09-04 2017-11-24 重庆市畜牧科学院 检测鸡鼻炎副鸡嗜血杆菌的环介导等温扩增试剂盒及其检测方法
CN109602701A (zh) * 2019-02-22 2019-04-12 湖北九州通中加医药有限公司 一种地塞米松磷酸钠注射液及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102552307A (zh) * 2012-03-13 2012-07-11 郑州百瑞动物药业有限公司 一种猪用复方黄芪多糖注射液及其制备方法
CN103083338A (zh) * 2012-04-23 2013-05-08 重庆金邦动物药业有限公司 增效复方安乃近注射液及其制备方法
CN103599071A (zh) * 2013-11-08 2014-02-26 杭州美亚药业有限公司 一种双链聚肌胞干粉的制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102552307A (zh) * 2012-03-13 2012-07-11 郑州百瑞动物药业有限公司 一种猪用复方黄芪多糖注射液及其制备方法
CN103083338A (zh) * 2012-04-23 2013-05-08 重庆金邦动物药业有限公司 增效复方安乃近注射液及其制备方法
CN103599071A (zh) * 2013-11-08 2014-02-26 杭州美亚药业有限公司 一种双链聚肌胞干粉的制备方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107385085A (zh) * 2017-09-04 2017-11-24 重庆市畜牧科学院 检测鸡鼻炎副鸡嗜血杆菌的环介导等温扩增试剂盒及其检测方法
CN109602701A (zh) * 2019-02-22 2019-04-12 湖北九州通中加医药有限公司 一种地塞米松磷酸钠注射液及其制备方法

Similar Documents

Publication Publication Date Title
CN101468099B (zh) 一种散风解表清热解毒的中药组合物及其制备方法
CN104304679B (zh) 一种复合维生素c、e免疫多糖微乳液制剂及其制备方法和应用
KR101139372B1 (ko) 한약재 미세캡슐을 이용한 증체목적용 돼지 사료첨가제 및 그 제조방법
CN106265736A (zh) 一种复方黄芪多糖注射液制备方法及应用
CN103039725B (zh) 保健型雏鸡开口饲料
CN102895326B (zh) 一种治疗小儿感冒的中药组合物及其制备方法
CN104784199A (zh) 激活免疫抗性治疗病菌感染的聚糖组合物
CN105943629A (zh) 一种治疗仔猪腹泻的中药复方制剂及其生产方法
CN102526568A (zh) 一种中药复方组合物
CN102188494B (zh) 一种治疗猪高热病的中药药物
CN104435069A (zh) 一种提高猪免疫功能的兽药组合物、应用及其制备方法
CN103721240A (zh) 一种治疗畜禽消化道细菌性感染的复方制剂及其制备方法
CN106577509A (zh) 孕期脂多糖导致子代大鼠高血压模型的建立方法
CN103720779B (zh) 高稳定的扶正解毒超微粉剂
CN102657702A (zh) 一种用于防治蛋鸡热应激的中药散剂
CN101380368A (zh) 治疗禽类肠炎、湿热泻痢的中药组合物
CN105641644A (zh) 一种肉鸡抗冷应激的药物
CN105641643A (zh) 一种肉鸡抗冷应激的双组分中药
CN105126081A (zh) 一种用于雏鸡开口的中西药组合物及其制备方法
CN108904592A (zh) 一种纯中药兽用抗病毒复方中药浓缩液和口服液及其制备方法
CN109498701A (zh) 一种防治鹅副粘病毒的中药组合物及其制备方法和应用
CN111035713A (zh) 一种百合地黄汤标准煎液制备方法
CN102688477A (zh) 一种治疗畜禽呼吸道疾病的药物组合物
CN105770004A (zh) 一种免疫增强剂及其预混料、浓缩料和配合料与应用
CN101297892A (zh) 治疗禽类肺热咳喘、呼吸道感染的中药组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170104

WD01 Invention patent application deemed withdrawn after publication